[1] Elderkin J, Al Hallak N, Azmi AS, et al. Hepatocellular carcinoma: surveillance, diagnosis, evaluation and management. Cancers (Basel), 2023, 15(21): 5118. [2] Song C, Lyu J, Liu Y, et al. Associations between hepatitis B virus infection and risk of all cancer types. JAMA Netw Open, 2019, 2(6): e195718. [3] Borza R, Salgado-Polo F, Moolenaar WH, et al. Structure and function of the ecto-nucleotide pyrophosphatase/phosphodiesterase (ENPP) family: tidying up diversity. J Biol Chem, 2022, 298(2): 101526. [4] Magkrioti C, Kaffe E, Aidinis V. The role of autotaxin and LPA signaling in embryonic development, pathophysiology and cancer. Int J Mol Sci, 2023, 24(9): 8325. [5] Zeng J, Zhang J, Sun Y, et al. Targeting EZH2 for cancer therapy: from current progress to novel strategies. Eur J Med Chem, 2022, 238: 114419. [6] Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma. Nat Rev Dis Primers, 2021, 7(1): 6. [7] Rizzo GEM, Cabibbo G, Craxi A. Hepatitis B virus-associated hepatocellular carcinoma. Viruses, 2022, 14(5): 986. [8] Jiang Y, Han Q, Zhao H, et al. The mechanisms of HBV-induced hepatocellular carcinoma. J Hepatocell Carcin, 2021, 8: 435-450. [9] 王可欣, 纪冬. 乙型肝炎病毒与肝细胞癌关系研究进展. 传染病信息, 2022, 35(2): 166-171. [10] Chang JI, Sinn DH, Cho H, et al. Clinical outcomes of hepatitis B virus-related hepatocellular carcinoma patients with undetectable serum HBV DNA levels. Dig Dis Sci, 2022, 67(9): 4565-4573. [11] Kim TS, Sinn DH, Kang W, et al. Hepatitis B virus DNA levels and overall survival in hepatitis B-related hepatocellular carcinoma patients with low-level viremia. J Gastroenterol Hepatol, 2019, 34(11): 2028-2035. [12] Wang MD, Li C, Liang L, et al. Early and late recurrence of hepatitis B virus-associated hepatocellular carcinoma. Oncologist, 2020, 25(10): e1541-e1551. [13] Liu Y, Kim ES, Guo H. Hepatitis B virus-related hepatocellular carcinoma exhibits distinct intratumoral microbiota and immune microenvironment signatures. J Med Virol, 2024, 96(2): e29485. [14] Matas-Rico E, Frijlink E, van der Haar Avila I, et al. Autotaxin impedes anti-tumor immunity by suppressing chemotaxis and tumor infiltration of CD8(+) T cells. Cell Rep, 2021, 37(7): 110013. [15] Meng J, Ruan X, Wei F, et al. High expression of ENPP2 is an independent predictor of poor prognosis in liver cancer. Medicine (Baltimore), 2023, 102(31): e34480. [16] Kaffe E, Katsifa A, Xylourgidis N, et al. Hepatocyte autotaxin expression promotes liver fibrosis and cancer. Hepatology, 2017, 65(4): 1369-1383. [17] Deng W, Chen F, Zhou Z, et al. Hepatitis B virus promotes hepatocellular carcinoma progression synergistically with hepatic stellate cells via facilitating the expression and secretion of ENPP2. Front Mol Biosci, 2021, 8: 745990. [18] Ma YN, Wang SS, Liebe R, et al. Crosstalk between hepatic stellate cells and tumor cells in the development of hepatocellular carcinoma. Chin Med J (Engl), 2021, 134(21): 2544-2546. [19] Myojin Y, Hikita H, Sugiyama M, et al. Hepatic stellate cells in hepatocellular carcinoma promote tumor growth via growth differentiation factor 15 production. Gastroenterology, 2021, 160(5): 1741-1754. [20] Huang JL, Fu YP, Gan W, et al. Hepatic stellate cells promote the progression of hepatocellular carcinoma through microRNA-1246-RORα-Wnt/β-catenin axis. Cancer Lett, 2020, 476: 140-151. [21] Ilango S, Paital B, Jayachandran P, et al. Epigenetic alterations in cancer. Front Biosci (Landmark Ed), 2020, 25(6): 1058-1109. [22] Liu Y, Yang Q. The roles of EZH2 in cancer and its inhibitors. Med Oncol, 2023, 40(6): 167. [23] Xu L, Lin J, Deng W, et al. EZH2 facilitates BMI1-dependent hepatocarcinogenesis through epigenetically silencing microRNA-200c. Oncogenesis, 2020, 9(11): 101. [24] Chen F, Byrd AL, Liu J, et al. Polycomb deficiency drives a FOXP2-high aggressive state targetable by epigenetic inhibitors. Nat Commun, 2023, 14(1): 336. [25] Yang X, Wan M, Yu F, et al. Histone methyltransferase EZH2 epigenetically affects CCNA1 expression in acute myeloid leukemia. Cell Signal, 2021, 87: 110144. |